INVAC-1 Anti-Cancer hTERT DNA Immunotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

February 28, 2018

Study Completion Date

June 1, 2018

Conditions
Solid Tumors
Interventions
BIOLOGICAL

INVAC-1

intradermal injection combined with electroporation

Trial Locations (2)

75010

Hôpital Saint Louis, Paris

75015

Hôpital Européen Georges Pompidou, Paris

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Keyrus Biopharma

OTHER

lead

Invectys

INDUSTRY

NCT02301754 - INVAC-1 Anti-Cancer hTERT DNA Immunotherapy | Biotech Hunter | Biotech Hunter